Heather Mannuel, MD
Medical Oncology · Baltimore, MDNPI 1720047129
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Pfizer at 33.1% of the total. 2024 is the largest year on record at $136, more than ten times the $11 reported in 2019. That places this record below the midpoint for medical oncology clinicians in MD, where the typical reported total is $4,199.
Across 14 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$107
- AbbVie$86
- Gilead$46
- AstraZeneca$22
- Amgen$22
- Merck$16
- plus $24 from 2 others
Across 286 payments — averaging $2292.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biontech SE$168K
- AVEO Pharmaceuticals, Inc.$150K
- Astrazeneca UK Limited$79K
- Janssen Research & Development, LLC$67K
- AbbVie$42K
- AstraZeneca$39K
- plus $112K from 6 others
What the payments were for
- Food & beverage$30795%
- Education$165%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$322 in reported general payments places this provider in the 30th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 25 | $631,478 |
| Abiraterone Acetate | 98 | $389,521 |
| XtandiEnzalutamide | 27 | $385,372 |
| OrgovyxRelugolix | 18 | $60,170 |
| OxycontinOxycodone Hcl | 15 | $5,133 |
| Oxycodone Hcl | 92 | $1,143 |
| Prednisone | 105 | $496 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $344 |
| Tamsulosin Hcl | 16 | $313 |
| Potassium Chloride | 23 | $203 |
| Duloxetine Hcl | 13 | $148 |
| Ondansetron Hcl | 11 | $122 |
| Tramadol Hcl | 21 | $107 |
| Lactulose | 12 | $91 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.